IP-10 detection in urine is associated with lung diseases
Open Access
- 22 November 2010
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 333
- https://doi.org/10.1186/1471-2334-10-333
Abstract
Background: blood cytokines and chemokines have been proposed as biomarkers for tuberculosis (TB). Recently, some immune mediators found in the urine of patients with renal dysfunctions have also been suggested as potential biomarkers. Finding biomarkers for TB in urine would present several advantages over blood in terms of collection and safety. The objective of this study was to investigate the presence of cytokines and chemokines in the urine of patients with pulmonary TB at the time of diagnosis. In a subgroup, the evaluation was also performed during TB treatment and at therapy completion. Patients with lung diseases other than TB, and healthy subjects were also enrolled.Methods: urine samples from 138 individuals, after exclusion of renal dysfunctions, were collected during an 18 month-period. Among them, 58 received a diagnosis of pulmonary TB, 28 resulted having lung diseases other than TB, and 34 were healthy subjects. Moreover, 18 TB patients, 9 of whom were tested 2 months after AFB smear sputum reversion and 9 of whom were cured of TB were also included. Cytokines and chemokines in urine were evaluated using a Cytometric-Bead-Array-Flex-Set. IP-10 detection in 49 subjects was also carried out in parallel by using an Enzyme Linked ImmunoSorbent Assay (ELISA).Results: IFN-γ, TNF-α, IL-2, IL-8, MIP-1α, MIP-1β and RANTES were poorly detected in all urine samples. Conversely, IP-10 was consistently detected in urine and its level was significantly increased in patients with lung disease compared to healthy subjects (p < 0.001). Increased IP-10 levels were found in both pulmonary TB and lung diseases other than TB. Moreover lower IP-10 levels were found in cured-TB patients compared to the levels at the time of diagnosis, and this difference was close to significance (p = 0.06). Interestingly, we demonstrated a significant correlation between the data obtained by flow cytometry and ELISA (r20.82, p < 0.0001).Conclusions: IP-10, in contrast to IFN-γ, TNF-α, IL-2, IL-8, MIP-1α, MIP-1β and RANTES, is detectable in the urine of patients with pulmonary diseases in the absence of renal dysfunctions. Moreover, the IP-10 level in cured-TB patients is comparable to that found in healthy subjects. More studies are needed to further investigate the clinical utility of these findings.Keywords
This publication has 40 references indexed in Scilit:
- Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practiceThe Lancet, 2010
- Urinary Biomarkers in Lupus NephritisClinical Reviews in Allergy & Immunology, 2010
- Implications of Storing Urinary DNA from Different Populations for Molecular AnalysesPLOS ONE, 2009
- Clinical Diagnostic Utility of IP-10 and LAM Antigen Levels for the Diagnosis of Tuberculous Pleural Effusions in a High Burden SettingPLOS ONE, 2009
- Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosisClinical and Experimental Immunology, 2009
- Cytokines in urine in elderly subjects with acute cystitis and asymptomatic bacteriuriaScandinavian Journal of Primary Health Care, 2009
- Differential Expression of Interleukin-4 (IL-4) and IL-4δ2 mRNA, but Not Transforming Growth Factor Beta (TGF-β), TGF-βRII, Foxp3, Gamma Interferon, T-bet, or GATA-3 mRNA, in Patients with Fast and Slow Responses to Antituberculosis TreatmentClinical and Vaccine Immunology, 2008
- Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancyThe Journal of Maternal-Fetal & Neonatal Medicine, 2007
- Short Communication:Influence of Active Tuberculosis on Chemokine and Chemokine Receptor Expression in HIV-Infected PersonsAIDS Research and Human Retroviruses, 2005
- Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.The Journal of Experimental Medicine, 1984